Beijing Quanyuhe Pharmaceutical Technology

Beijing Quanyuhe Pharmaceutical Technology is a clinical-stage biotechnology company based in China, primarily focused on the development of innovative small molecule therapeutics for metabolic and inflammatory diseases. The company's lead program, QYH211, is a potent and selective URAT1 inhibitor designed to treat hyperuricemia and gout by promoting uric acid excretion. Quanyuhe aims to address significant unmet medical needs in the chronic disease space through targeted drug discovery and rigorous clinical validation. The company operates out of Beijing and maintains a pipeline focused on high-prevalence metabolic conditions.